Top Tweets for #DMARD
💉Monitoring blood tests for patients on DMARDs?
Researchers at @manchesteruni & @UniofNottingham want to learn more about #DMARD monitoring practices across the UK.
Please take the survey to help inform future guidance & safer care: https://t.co/4dLE7pNpBH
@KearsleyFleet
Risk of interstitial lung disease (ILD) and safety outcomes across #DMARD classes in #rheumatoid #arthritis (RA) and RA-ILD (Korean nationwide cohort study, 26,120 RA patients, 641 with RA-ILD)
◦ ILD incidence was similar across all DMARD classes (anti-TNF, non-anti-TNF biologics, JAK inhibitors, conventional synthetic DMARDs).
◦ No class increased risk of developing ILD or ILD-related hospitalizations.
◦ Non-anti-TNF biologics (abatacept, rituximab, tocilizumab) showed significantly higher risks compared to conventional synthetic DMARDs:
- Hospitalization, especially pneumonia-related (RA: adjusted hazard ratio [aHR] 1.30; RA-ILD: aHR 1.35)
- Serious infections (RA: aHR 1.16; RA-ILD: aHR 1.51)
- All-cause mortality (RA: aHR 4.09; RA-ILD: aHR 4.31)
- Strongest signals in RA-ILD patients, including higher pneumonia recurrence
◦Anti-TNF and JAK inhibitors had safety profiles comparable to conventional synthetic DMARDs (no significant increase in hospitalization, infection, or mortality).
◦ Risk of major adverse cardiovascular events did not differ significantly across DMARD classes.
These findings indicate that while none of the studied DMARD classes appeared to increase the risk of developing or worsening ILD itself, non-TNFi biologics carried the highest burden of serious safety events —particularly infection-related complications and mortality— in both general RA and RA-ILD patients. This study underscores the need for particularly close monitoring for infections (especially pneumonia) when using non-TNFi biologics in these populations.
*Lee KA, Lee B, Kim HS. Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD. Semin Arthritis Rheum. 2026;77:152921.
🔗https://t.co/aeK7BUtRq6
![alb_giraldo's tweet photo. Risk of interstitial lung disease (ILD) and safety outcomes across #DMARD classes in #rheumatoid #arthritis (RA) and RA-ILD (Korean nationwide cohort study, 26,120 RA patients, 641 with RA-ILD)
◦ ILD incidence was similar across all DMARD classes (anti-TNF, non-anti-TNF biologics, JAK inhibitors, conventional synthetic DMARDs).
◦ No class increased risk of developing ILD or ILD-related hospitalizations.
◦ Non-anti-TNF biologics (abatacept, rituximab, tocilizumab) showed significantly higher risks compared to conventional synthetic DMARDs:
- Hospitalization, especially pneumonia-related (RA: adjusted hazard ratio [aHR] 1.30; RA-ILD: aHR 1.35)
- Serious infections (RA: aHR 1.16; RA-ILD: aHR 1.51)
- All-cause mortality (RA: aHR 4.09; RA-ILD: aHR 4.31)
- Strongest signals in RA-ILD patients, including higher pneumonia recurrence
◦Anti-TNF and JAK inhibitors had safety profiles comparable to conventional synthetic DMARDs (no significant increase in hospitalization, infection, or mortality).
◦ Risk of major adverse cardiovascular events did not differ significantly across DMARD classes.
These findings indicate that while none of the studied DMARD classes appeared to increase the risk of developing or worsening ILD itself, non-TNFi biologics carried the highest burden of serious safety events —particularly infection-related complications and mortality— in both general RA and RA-ILD patients. This study underscores the need for particularly close monitoring for infections (especially pneumonia) when using non-TNFi biologics in these populations.
*Lee KA, Lee B, Kim HS. Risk of ILD and safety outcomes across DMARD classes in rheumatoid arthritis and RA-ILD. Semin Arthritis Rheum. 2026;77:152921.
🔗https://t.co/aeK7BUtRq6](https://pbs.twimg.com/media/G-6HffXXIAAIH6A.jpg)
💉Monitoring blood tests for patients on DMARDs?
Researchers at @manchesteruni & @UniofNottingham want to learn more about #DMARD monitoring practices across the UK.
Please take the survey to help inform future guidance & safer care: https://t.co/4dLE7pNpBH
@KearsleyFleet
💉Monitoring blood tests for patients on DMARDs?
Researchers at @manchesteruni & @UniofNottingham want to learn more about #DMARD monitoring practices across the UK.
Please take the survey to help inform future guidance & safer care: https://t.co/4dLE7pNpBH
@KearsleyFleet
💉Monitoring blood tests for patients on DMARDs?
Researchers at @manchesteruni & @UniofNottingham want to learn more about #DMARD monitoring practices across the UK.
Please take the survey to help inform future guidance & safer care: https://t.co/4dLE7pNpBH
@KearsleyFleet
🚨 Which is considered the first-line DMARD for rheumatoid arthritis (RA)?
🔴A) Leflunomide
🔴B) Methotrexate
🔴C) Sulfasalazine
🔴D) Hydroxychloroquine
#MedTwitter #RA #DMARD
A recent study shows that the activity of #ACPA-expressing memory B cells is associated with disease phenotype in #rheumatoid #arthritis (RA), may predict imminent RA onset and possibly identify patients in immunological #remission capable of reaching sustained #DMARD-free remission (SFDR). The profile observed in RA (high #CD80, low #CD32, abundant #plasmablasts) is reminiscent of T cell-driven, germinal centre-derived B cell responses, while the phenotype observed in SFDR/nonconverting clinically suspect arthralgia suggests that certain disease features may be absent that otherwise (chronically) stimulate ACPA-expressing B cells. These features may be an important step towards understanding how disease chronicity develops in RA.
*Blomberg NJ et al. Autoreactive B cells in extremes of rheumatoid arthritis disease phenotypes. Annals of the Rheumatic Diseases, 2025.
🔗https://t.co/rC8A6YTGOT
A large nationwide study examining all biological and targetet synthetic #DMARD classes, found that #rituximab had the highest incidence rates of major adverse #cardiovascular events (MACE) and numerically increased risk of MACE, as well as the shortest median duration to MACE development, compared with TNF inhibidors exposures, regardless of prevalent cardiovascular disease history. However, this study did not demonstrate a statistically significant higher risk of MACE with either non-TNF and JAK inhibidors exposures compared to TNF inhibidors exposures.
*Sendaydiego X, Gold LS, Dubreuil M, Andrews JS, et al. Comparative safety of biologic and targeted synthetic disease-modifying anti-rheumatic drugs for cardiovascular outcomes in rheumatoid arthritis. Rheumatology (Oxford). 2025 Feb 12
🔗https://t.co/grke86NYLP
Our updated #biologic #DMARD safety #guidelines aim to ensure the highest standards in managing inflammatory arthritis. Your input will help us make these guidelines more practical, relevant, and rooted in real-world experience. Please share your views 👉 https://t.co/uS6oHSLJsk
Our updated #biologic #DMARD safety #guidelines aim to ensure the highest standards in managing inflammatory arthritis. Your input will help us make these guidelines more practical, relevant, and rooted in real-world experience. Please share your views 👉 https://t.co/uS6oHSLJsk
Checklist for pregnancy management of rheumatoid arthritis.
#Rheumatology #RheumatoidArthritis #Pregnancy #DMARD
*From: Nakai T, Fukui S, Ozawa H, Kitada A, Okada M, Kishimoto M. Management of pregnant with rheumatoid arthritis: Preconception care, pregnancy and lactation strategies, and maternal-fetal outcomes. Best Pract Res Clin Rheumatol. Published online November 20, 2024.
🔗https://t.co/ofHokvs776
Are weight loss drugs in #high #BMI
In
#Rheumatoid #arthritis
A #DMARD?
Yr in preview #ACR24 @RheumNow @ACRheum
@ACEJointHealth Have a look members and followers if you’re interested in #dmard use in pregnancy. Great overview! #ACR24 ⬇️
⭕️GCA- PMR spectrum disease
categories of clinical features:
✴️Cranial
✴️Ischaemic
✴️Constitutional
✴️Polymyalgic
#GPSD #GCA #PMR #inflammation #DMARD #Steroid #glucocorticoids
By @profbdasgupta & colleagues
https://t.co/iIDxT6taVz
#opportunistic inf in #autoimmune dz
🎤 @khyrich
👉#herpes zost is ⬆️⬆️,esp😳#lupus (💉 >18yo🇺🇸)
👉#HBV react ⬆️⬆️ w/ RTX (9.1%) >>TNFi, JAKi, IL-6
👉 🙅♂️ #TB repeat 🧪 on #DMARD if 🚫new risk fact/gap⚠️
🔗#eular 2022 guide:
https://t.co/PIpGpTrH28
#eular2024
#rheumx
@RheumNow
New #rheumatoid #arthritis is associated in many with
⬆️pain
⬆️fatigue
⬆️anxiety
⬆️depression
But within 3 months of #DMARD Rx
There is hope! @Susanbartlett12
@CRASCRRheum #ASM24
🔮One predictor of which RA patients will respond to #DMARD therapy could be the gut microbiota in their stool samples, according to a study led by @_NDanckert. #MedTwitter #HealthNews
Find out more at Healio 🔽
https://t.co/dbihw0Lg46
Last Seen Hashtags on Sotwe
momson()()()()()()()()()()()()()()()() +filter:native_video
Seen from United States
nolimit()*********** + filter:native_video
Seen from Korea
ometv
Seen from Italy
Teenager()+filter:native_video
Seen from Colombia
ルーティーンズ
Seen from Japan
DeeWilliam
Seen from Peru
hkcd
캠톡
Seen from Korea
putipobre
Seen from Italy
omegle()****** -- filter:videos
Most Popular Users
Elon Musk 
@elonmusk
240.9M followers
Barack Obama
@barackobama
119.2M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Cristiano Ronaldo
@cristiano
111.6M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
97.9M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.1M followers
KATY PERRY
@katyperry
88.2M followers
Taylor Swift
@taylorswift13
82.1M followers
Lady Gaga
@ladygaga
73.6M followers
Virat Kohli
@imvkohli
70.7M followers
Kim Kardashian
@kimkardashian
70M followers
YouTube
@youtube
68.7M followers
Bill Gates
@billgates
64.2M followers
Neymar Jr
@neymarjr
63.6M followers
The Ellen Show
@theellenshow
62.4M followers
CNN
@cnn
61.8M followers
Selena Gomez
@selenagomez
61.3M followers
X
@x
60.8M followers